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Abstract: Toxoplasmosis is an infectious disease with paramount impact worldwide, affecting many
vulnerable populations and representing a significant matter of concern. Current therapies used
against toxoplasmosis are based essentially on old chemotypes, which fail in providing a definitive
cure for the disease, placing the most sensitive populations at risk for irreversible damage in vital
organs, culminating in death in the most serious cases. Antimalarial drugs have been shown to
possess key features for drug repurposing, finding application in the treatment of other parasite-borne
illnesses, including toxoplasmosis. Antimalarials provide the most effective therapeutic solutions
against toxoplasmosis and make up for the majority of currently available antitoxoplasmic drugs.
Additionally, other antiplasmodial drugs have been scrutinized and many promising candidates
have emanated in recent developments. Available data demonstrate that it is worthwhile to explore
the activity of classical and most recent antimalarial chemotypes, such as quinolines, endoperoxides,
pyrazolo[1,5-a]pyrimidines, and nature-derived peptide-based parasiticidal agents, in the context
of toxoplasmosis chemotherapy, in the quest for encountering more effective and safer tools for
toxoplasmosis control or eradication.
Keywords: Toxoplasma gondii; Plasmodium spp.; antimalarial drugs; drug repurposing; quinolines;
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1. Introduction
Infectious diseases continue to represent leading causes of the global burden at social, economic,
and public health levels [1–4]. Several parasite-borne infectious diseases are especially threatening
because of their global impact, including malaria, leishmaniases, and toxoplasmosis. Due to its
extended burden across several millennia, malaria has duly benefitted from intense research during the
last century and, in view of the spread of parasites’ resistance against antimalarials in use, the efforts
must continue [5,6]. Malaria-related research has enabled a better understanding of various aspects
attributed to the disease, namely those associated with transmission, infection, and progression inside
the human host, including related symptoms and molecular mechanisms, leading to the development
of prophylactic measures as well as of structure-based and target-based antimalarial drugs [7]. On the
contrary, investments in research related to leishmaniases and toxoplasmosis are far from those accorded
to malaria, and most drugs used against these diseases were developed to treat other vector-borne
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pathologies, including malaria [8]. Toxoplasmosis is a neglected disease, with an urgent need for action
since one third of the population is chronically infected with Toxoplasma gondii [9].
Toxoplasma gondii is a required intracellular protozoan parasite firstly described in 1908 by Nicolle
and Manceaux after the observation of an arch-like structure in a rodent, a feature that originated in
the designation of the Toxoplasma genus (“toxo=arc, plasma=form”) [10]. This parasite affects most
warm-blooded mammals; however, its only definitive host known to date is the cat and all other
members of the Felidae family. The definitive host is where sexual reproduction takes place, in this case
in the cat’s intestine, leading to the formation of infective oocysts. Fecal expulsion of oocysts gives rise to
the primary infection route of the parasite’s intermediate hosts, a fecal–oral transmission route through
contact with soil, water, or food contaminated with sporulated oocysts [2]. Once inside the intermediate
host, the oocysts differentiate into fast-spreading tachyzoite forms of T. gondii, which infect all types of
nucleated cells, where they reproduce asexually, encysting subsequently in immunoprivileged organs,
such as neural and lymphatic tissues, heart, and lungs, under a dormant minimally metabolically active
bradyzoite form of T. gondii [11,12]. This process consists in a protective mechanism, which allows the
parasite to evade the immune system. However, upon failure of the immune system, cysts rupture,
releasing bradyzoites into the bloodstream, which rapidly convert into the tachyzoite active form,
and reactivating the infection, which usually culminates with a clinical presentation of the disease [12].
Parasite dissemination throughout the intermediate host’s tissues is responsible for the introduction
of other transmission routes with high impact to the human host, in which we can include the foodborne
transmission of tissue cysts through the ingestion of raw or poorly cooked meats, iatrogenic transmission
through organ transplantations and blood transfusions, and vertical transplacental transmission from
mother to fetus [13].
Healthy individuals infected with this parasite usually do not develop symptoms, because the
immune system is able to fight the infection and prevent further outbursts. However, immunodeficient
individuals are at high risk of developing severe symptoms, including brain damage, since the brain
is the most susceptible organ to primary infections and reactivation of toxoplasmosis. Another
concerning matter to take into account is the vertical transmission of the parasite, which, if left
untreated, may critically affect the fetus, causing irreversible and possibly fatal consequences [14].
Infection with T. gondii acquired during pregnancy or just before conception places the mother at risk
of accumulation of tachyzoites in the placenta, which are transmitted to the fetus. Quite interestingly,
congenital transmission rates appear to be lower in cases where the mother contracts the parasite in the
earlier stages of the pregnancy rather than in the later stages, whereas the consequences to the fetus are
far more detrimental in the cases involving an early onset of infection [15]. Specific measures, such as
screening tests for early detection of maternal infection and early initiation of treatment, are therefore
mandatory for the prevention of vertical transmission.
Furthermore, although infections by encysted bradyzoite forms of T. gondii in immunocompetent
human hosts have been associated with latency of the disease and an asymptomatic clinical state,
recent studies have come to refute such conclusions, connecting these stages of infection with the
appearance of alterations in the intermediate host [16–20]. Following alterations in tryptophan
metabolism, the human host becomes susceptible to mental disorders, such as schizophrenia,
anxiety, and depression [16–18]. Studies have also shown behavioral changes in rodents induced by
T. gondii, namely a decreased fright response to cat odor, as a result of lower renewal levels in host
neurotransmitters [20].
Toxoplasmosis is a public health issue that demands much effort towards the implementation of
preventive and therapeutic measures in the most vulnerable populations, in order to tackle the infection
and prevent the disease from evolving to more severe outcomes. Additionally, novel therapeutic
alternatives are necessary to provide more efficient treatment regimens and achieve parasite eradication.
The main current shortcomings in the available treatment options are their inefficacy against all of the
parasitic stages, namely the acute tachyzoite stage and the chronic bradyzoite stage, where reactivation
of the disease becomes a possibility, as happens, for example, in ocular toxoplasmosis and in
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immunosuppressed individuals, the unequal susceptibility and/or resistance of the parasites to the
currently available drugs, and, also, the high prevalence of severe adverse effects from medication to
the carrier of the disease [21].
2. Treatment
2.1. Currently Available Drugs
When addressing therapies against infections by Toxoplasma gondii, several focal points should be
contemplated. Firstly, toxoplasmosis can manifest through different clinical expressions, according to
the stage of the infection and the status of the host’s immune system. Given the parasite’s appetence
for immunoprivileged tissues, the main clinical presentations occur at ocular or central nervous
system (CNS) levels, although pulmonary and multi-organ effects may also develop in severely
immunocompromised patients. Additionally, the parasite’s ability to encyst, protecting itself from
external agents, makes it difficult to tackle this stage of the disease, especially for cerebral cysts,
where the blood–brain barrier emerges as an additional constraint for directed therapies [22].
Treatment guidelines for toxoplasmosis recommend, as first-line therapies for all of the
clinical manifestations, a combination between three agents: Pyrimethamine and sulfadiazine,
which act synergistically through inhibition of the folate synthetic pathways of the parasite,
disrupting its DNA synthesis; and folinic acid, which acts as a coadjuvant in restoring the
host’s folate levels [9,22,23]. In hypersensitive patients, protein synthesis inhibitor antimicrobials,
such as clindamycin, clarithromycin, azithromycin, or the mitochondrial electron-transport inhibitor
atovaquone, may be used as replacements for sulfonamides. The combination of trimethoprim with
sulfamethoxazole (co-trimoxazole) is also used because its efficacy was shown to match those of the
previously mentioned drugs (Table 1).
Table 1. Chemotherapeutic approaches commonly used for toxoplasmosis.
Type of Disease Front-line Treatment Alternatives
Congenital toxoplasmosis
Pyrimethamine + Sulfadiazine + Folinic acid
Spiramycin for prophilaxis






Congenital toxoplasmosis can be approached therapeutically in two distinct ways, whether
it is intended for prophylaxis from transplacental transmission or for the treatment of acquired
progressive fetal infection, although therapeutic regimens may vary in different geographic regions [15].
Spiramycin is the most recommended drug for a prophylactic approach, usually in the earlier stages of
pregnancy where no definitive fetal exams can be performed to confirm the disease. In later stages
or in confirmed fetal infection, the first-line combination therapy for toxoplasmosis, consisting of a
pyrimethamine/sulfadiazine/folinic acid regimen, is maintained, although a switch to prophylactic
spiramycin may also be considered in late-stage infections with negative fetal results [24].
Although currently available drugs allow for elimination of an active infection, these drugs
present several side effects, such as renal, hepatic, and hematological toxicity and hypersensitivity [23].
To circumvent these issues and to allow for complete eradication of the parasite, efforts must be made
towards the development of novel chemotherapies. Health organizations have adopted a new method
of drug development for new purposes based on the investigation of the potential of drugs or drug
candidates that are already in use or under development, allowing evasion or minimization of the
need for safety tests and drug profile studies. The implementation of such strategies may promote a
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faster and low-cost expansion of the libraries of promising molecules to combat toxoplasmosis. In this
context, the antimalarial arsenal may provide a pool of suitable antitoxoplasmic candidates.
2.2. Drug Repurposing in Toxoplasmosis Therapy
2.2.1. Can Antimalarials Treat Toxoplasmosis?
Toxoplasma gondii belongs to the family Sarcocystidae and to the phylum Apicomplexa. This phylum
includes other pathogens, such as Plasmodium spp. (malaria), Cryptosporidium spp. (cryptosporidiosis),
etc., but the ones that mostly affect human public health are T. gondii and Plasmodium spp., the causative
agents for toxoplasmosis and malaria, respectively. All of the aforementioned pathogens are obligatory
intracellular parasites and share a variety of common features. Among them, one which deserves
distinctive attention is the apical complex, the hallmark of the Apicomplexa phylum, an indispensable
structure for the recognition and subsequent invasion of host cells [25]. Most of these parasites
also contain the apicoplast, an essential plastid organelle derived from an endosymbiotic process
with a seaweed, which is crucial for the biosynthesis of essential parasitic biomolecules, like fatty
acids (type II fatty acid pathway), iron-sulfur clusters, the heme group, and isoprenoid precursors
(the non-mevalonate pathway) [25,26]. The high similitude in morphology and biochemistry
between T. gondii and Plasmodium spp. makes them especially interesting from the therapeutic
viewpoint, since common metabolic pathways and organelles may serve as targets for the same drugs,
as happens with some of the currently available antitoxoplasmic drugs pyrimethamine, sulfonamides,
and atovaquone, which were initially designed and developed for the treatment of malaria [27,28].
The apicoplast ribosome inhibitors, such as clindamycin and doxycycline, also fit these criteria,
being currently used for the treatment of acute toxoplasmosis and malaria chemoprophylaxis [26].
Hence, drug repurposing stems as a useful approach for drug development in these parasitic illnesses.
In fact, several studies focus on the evaluation of antimalarial compounds on T. gondii and some even
focus concomitantly on therapeutics targeting both parasites [27,29–31].
Therapies and candidates for toxoplasmosis have been reviewed elsewhere [19,31–34] and,
therefore, for the scope of this work, our aim is to discuss and further explore those classes of
compounds that are active and/or promising against infections by T. gondii, with a previous or current
impact on malaria.
2.2.2. Quinolines
The quinoline scaffold (highlighted in blue in Figures 1 and 2) is a heterocyclic aromatic structure
formed by the fusion between a benzene ring and a pyridine ring. Following the isolation of quinine
from the bark of the cinchona tree, quinolines were the first class of medicines used against malaria
in the western world [35–37]. For many years quinoline-based therapeutics were the leading agents
in the treatment of malaria, and still remain within the therapeutic options against Plasmodium spp.
infections nowadays [6]. In addition, the quinoline chemotype offers effective therapeutic solutions for
a variety of different diseases, including infections from bacteria, viruses, fungi, parasites, and, in some
cases, even in non-infectious illnesses [38]. Quinolines have also been shown to be effective against
infections caused by T. gondii, in both acute and chronic phases [29,30,32,39–42].
Endochin-Like Oxoquinolines (ELQs) and Quinoline-Based PPQ-8
As stated above, quinolines represent one of the major classes of compounds explored for
antimalarial chemotherapy. Many quinoline-based drugs were designed and used since the first half
of the last century, some of which are still used nowadays against susceptible strains of Plasmodium,
but the substantial capacity of the parasite to evolve and acquire resistance to those agents required
many efforts in developing more potent, less toxic, and well-tolerated molecules [38,43]. Endochin
(structure (a), Figure 1) was the first 4-oxo-quinoline (also called quinolone) to be studied in the context
of malaria chemotherapy, but, due to its rapid metabolism, it did not fit the criteria to become an
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effective antimalarial drug [44–47]. However, the discovery of this compound’s high antiplasmodial
activity prompted the use of its core structure as a lead framework in the development of many
endochin-like quinolone derivatives [38], targeting parasites’ organelles, namely the mitochondrial
ubihydroquinone, A cytochrome c oxireductase complex often referred to as the cytochrome bc1
complex, composed of two catalytically active domains comprising the hydroquinone oxidation (Qo)
and the quinone reduction (Qi) sites [48]. This complex is a vital structure for the parasite’s respiratory
chain and for the biosynthesis of essential molecules [49], and its relevance in this field grew since it
was established as the therapeutic target in P. falciparum of currently available antimalarial atovaquone
(structure (b), Figure 1) [50].Molecules 2020, 25, x FOR PEER REVIEW 5 of 16 
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T e apicomplexan cytochrome bc1 complex is highly conserved within the phylum, including in
T. gondii, with the latter being significantly affected by endochin-like quinolones at both the Qo and Qi
sites of this enzyme complex [33,40–42]. In fact, ELQs revealed high efficacies, with singl -dose cures
being observed in some cases, d, as such, some ELQs entered the preclinical phase of dev lopment
bot ag inst toxoplas osis and m laria [40,51,52]. Promising antitoxo lasmic ca didates include
ELQ-271 and ELQ-316 (Figure 1; compounds (c) and (d)), which were shown to possibly inhibit the
cytochrome bc1 complex, with high selectivity t the parasitic c mpl x comparatively to the huma
cytochrome bc1 complex [41,42]. Regarding the site of action, the authors suggest that ELQ-271 and
p ssibly other endochin-like quinolones inhibit the divergent Qi site, rather than t highly c nserved
Qo site inhibited by atovaquone [41,42], although structural studies indicate that small changes within
the quinol ne fr mework may have a significant impact in th ctivity of the compounds as well as the
binding target [53]. Early docking studies performed in silico at the yeast Q site of the bc1 protein
complex of P. falciparum [54] i dicated that both the carbonyl and the N-H group of the 4-oxoquinoline
framew rk are relevant for the potent activity of quinolones. The carbonyl appears to be oriented
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to enable the formation of H-bonding between the carbonyl and a protonated imidazole nitrogen of
His181, while the quinolone N-H is involved in a water-mediated H-bond with the cytochrome b
residue Glu272. It is also noteworthy that endochin and the ELQ candidates bear the possibility of
quinolone-hydroxyquinoline tautomerism [55], which may impact antiparasitic activity.
Recently, McConnell et al. studied the inhibitory effect of a library of ELQs on the cytochrome
bc1 complexes of P. falciparum and T. gondii parasites, having concluded that, beside ELQ-271 and
ELQ-316, the very promising candidate ELQ-400 (compound (e), Figure 1) was able to inhibit both
the Qi and Qo sites, possibly due to the aforementioned structural flexibility, as well as the favorable
substitution pattern [40,56]. In toxoplasmosis, this compound is thought to act on both acute and
chronic stages, as demonstrated by the lack of parasites in the mice tissues, including the brain,
suggesting an ability of the compound to cross the blood–brain barrier as well as a strong antiparasitic
effect [40]. Additionally, the compound showed better physicochemical characteristics than previously
evaluated ELQs, highlighting this compound’s and the quinoline class’s striking features for further
scrutinization in the context of malaria and toxoplasmosis chemotherapies and, potentially, for treating
infections due to other apicomplexan parasites.
The attractive features of the quinoline scaffold in the context of toxoplasmosis prompted Elgawad
and co-workers to evaluate the effect of the quinoline-based hybrid 4-(2-chloroquinolin-3-yl)-
6-(2,5-dimethoxyphenyl)-2-oxo-1,2-dihydropyridine-3-carbonitrile, also known as PPQ-8 (Figure 2),
against acute and chronic toxoplasmosis mouse models [39]. The compound stood out, as it has
evidenced very promising results in decreasing the overall parasitic burden and an ability to cross the
blood–brain barrier, promoting the degeneration and reduction of T. gondii cysts containing bradyzoites,
one of the major problems in toxoplasmosis, characteristic of the disease’s chronic phase. The treatment
of infected mice in the acute phase with PPQ-8 led to disarrangement in the morphology of tachyzoites
and consequently a significant decrease in the parasite’s distribution throughout the tissues, namely in
the liver and spleen, where a considerable decrease in inflammation and histopathological changes
was observed [39].
Although the authors were not able to determine the exact therapeutic target, the information
available suggests a possible inhibition of the apicoplast by the quinoline core, leading to the parasite’s
death, as well as a potential interference with the replicative cycle through disruption of DNA
topoisomerases [39]. The latter may possibly be justified by the resemblance of PPQ-8 with antibacterial
fluoroquinolones, known as topoisomerase inhibitors, which in fact were shown to exhibit high
efficacies and survival rates in acute-phase infected mouse models of toxoplasmosis and also in some
P. falciparum models [19,57].
2.2.3. Artemisinin and Related Endoperoxides
As for the quinoline class, the first use of endoperoxides against parasitic illnesses emerged from
the discovery of the antimalarial properties in Artemisia annua, a herb used in traditional Chinese
medicine [58,59]. Artemisinin (structure (a), Figure 3), a sesquiterpene lactone that contains a peroxide
bridge essential for its activity, is one of a very limited number of naturally occurring endoperoxides
and was shown to inhibit chloroquine-resistant strains of Plasmodium falciparum parasites at low
nanomolar concentrations [60], with efficacies comparable to those exhibited by chloroquine and
mefloquine when tested against the corresponding sensitive strains. Artemisinin was initially used to
treat malaria but limitations, such as low solubility in both water and oil, a short half-life, and its fast
metabolization to dihydroartemisinin, DHA, (structure (b), Figure 3), which is neurotoxic, demanded
for more soluble and less toxic semi-synthetic derivatives, commonly known as artemisinins [61–63].
Additionally, low yields, high production costs, and inefficacy against all strains of Plasmodium
prompted the development of synthetic endoperoxides [62–65]. Nevertheless, artemisinin and some of
its semi-synthetic derivatives, namely DHA, artemether, artesunate, and artelinate (represented as
structures b, c, d, and e in Figure 3, respectively), when used in combination with other longer-lived
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antimalarials, provide the artemisinin-based combination therapy (ACT), which is used as frontline
treatment for malaria [6].
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Figure 4. Structural representation of the antitoxoplasmic artemisinin derivative A2, studied by 
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2.2.4. Pyrazolo[1,5-a]pyrimidines 
Figure 3. Structural representation of endoperoxides used as antimalarials: artemisinin (a),
dihydroartemisinin (b), artemether (c), artesunate (d), and artelinate (e), highlighting the peroxide bond.
Recent data shows that artemisinin and its derivatives also exhibit activity against
T. gondii [27,66–71], yet different potencies reinforce the possibility of different targets being affected
in each case and/or differences in drug accumulation among different parasite species. While in
Plasmodium it has been proposed that endoperoxides may have an important role in heme detoxification
and the production of reactive species mediated by the host’s heme iron, contrasting studies in T. gondii
appear to indicate that the main mechanism of action of this class of compounds in T. gondii is associated
with their interference with calcium homeostasis, affecting all parasitic processes that are dependent
on this mineral [65,72–74].
Regarding the activity of endoperoxides against toxoplasmosis, both acute and chronic phases
were shown to be affected, although potencies in some cases fell short and were rather variable among
the tested derivatives [66–71]. Recently, Deng and colleagues performed in vitro and in vivo studies to
evaluate the activity of a library of artemisinin derivatives and their selectivity towards the parasite [67],
with the in vitro data demonstrating that all derivatives tested exhibited better selectivity than the
controls DHA and spiramycin. From the library investigated, compound A2 (Figure 4) emerged as the
most promising lead, showing the highest selectivity in vitro and also a very promising inhibition of
the acute-phase tachyzoites in vivo, since its action significantly decreased invasion of the peritoneal
cavity in mice and led to a reduction in hepatic and splenic inflammatory processes [67]. These results
show that antimalarial endoperoxides and their derivatives undoubtedly deserve further investigation
as possible antitoxoplasmic drug candidates.
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2.2.4. Pyrazolo[1,5-a]pyrimidines
Pyrazolo[1,5-a]pyrimidines are a class of structurally challenging compounds with interesting
properties [75], including promising antibacterial activity, as seen, for example, in preliminary studies
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against Mycobacterium tuberculosis [76,77], as well as antiparasitic activity against Plasmodium spp. [78,79]
and other protozoans, such as Trypanosoma spp. and Leishmania spp. [80,81]. In addition, studies
conducted by Spalenka et al. led to the identification of a pyrazolo[1,5-a]pyrimidine, shown to attain
antitoxoplasmic activity at low micromolar inhibitory concentrations, with high selectivity towards the
parasite [31]. The work group evaluated a series of antimicrobial derivatives from the pathogen box,
and pyrazolopyrimidine MMV022478 (Figure 5) emerged as one of the most encouraging candidates
for T. gondii inhibition. This compound was selected based on structural similarities with the currently
available drug pyrimethamine, indicating that the suspected drug target is the dihydrofolate reductase
enzyme (DHFR). These findings revealed positive features of the pyrazolo[1,5-a]pyrimidine scaffold
and stimulated research for this class as potential selective DHFR inhibitors in T. gondii.
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2.2.5. Immunomodulatory Agents
Antimicrobial Peptides
Increasing incidence rates of drug resistance in many therapeutic fields, namely bacterial and
parasitic diseases, stimulated the search for different sources of therapeutic agents against these diseases
to circumvent current difficulties. Antimicrobial peptides (AMPs) are a class of compounds that
emerged as promising antimicrobial alternatives to present chemotherapies [82–84]. These molecules
are very versatile, having numerous activities that include antiviral, antifungal, anti-mitogenic,
anti-cancer, and anti-inflammatory [85]. Morphologically, AMPs are the first defense elements of
the innate immune system produced by a variety of organisms, including humans, and they are
responsible for the elimination of intruder entities through the disruption of cytoplasmic membranes,
leading to cell damage and death, as well as immunomodulation through activation or suppression
of key immunomodulatory biomolecules [82–84,86,87]. Recent studies have highlighted the activity
of such peptides against parasitic diseases, with malaria being one of the leading parasitic illnesses
researched in this field [88–99]. New data incorporating AMPs have also surfaced as a promising
source of antitoxoplasmic candidates [97,100–107].
The majority of the studied AMPs act on tachyzoites, i.e., on the proliferative stage of T. gondii,
inhibiting this process through direct killing of the parasite in the bloodstream and by reducing primary
cell infection. Although these are aimed solely at an acute phase of the disease, some results show
better activities than currently available drugs pyrimethamine, sulfadiazine, or spiramycin [105–107].
Lee et al. studied the activity of antimicrobial peptide interferon (IFN)-γ–inducible immunity-related
GTPase (Immunity-related GTPase, IRG protein) on the intracellular reproductive stage of T. gondii
tachyzoites by acting on the parasitophorous vacuole [108], having found that IRG proteins are relevant
effector agents in the process of vacuole disruption and breakdown, reinforcing the multifarious
character of antimicrobial peptides and their potential use in the therapy of toxoplasmosis, targeting
multiple stages of the cycle, and bypassing the parasite’s ability to acquire sophisticated mechanisms
of drug resistance.
Lycosin-I is a cationic peptide derived from the venom of the spider Lycosa singorensis. This peptide
acts as a potent inhibitor against inflammation, malignant tumors, and microorganisms, essentially
affecting cells carrying charged cytoplasmic membranes. Recent studies have shown that lycosin-I
is also effective against infections with T. gondii and acts through disruption of the cell plasma
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membrane [58,59]. The interaction between lycosin-I and the negatively charged intruder cell mediates
the disruption of the membrane, exposing the compound to the intracellular environment, where it
can concomitantly affect internal structures and lead to organelle damage, loss of shape, vacuolization,
and breakdown [58,59]. Additionally, this molecule was shown to inhibit intracellular proliferation of
tachyzoites, with inhibition rates higher than those observed in treatments with sulfadiazine [109].
Apart from the direct mechanism of inhibition, lycosin-I was also shown to activate an immune
response through an increase in the production of interleukins IL-6 and IL-8 cytokines [109]. Scheme 1
depicts the inhibition pathways mediated by lycosin-I.
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Fungal Secondary Metabolites
Secondary metabolites are organic compounds produced by a variety of organisms, including
fungi, bacteria, and plants. Fungi represent a valuable source of secondary metabolites with impact
in anti-infectious therapies and can be classified into four distinct groups: Cyclic depsipeptides,
peptaibiotics, non-depsipeptide cyclic lipopetides, and non-peptaibiotic linear lipopeptides. Similar
to AMPs, these compounds act as defense mechanisms against external stimuli [110,111]. Cyclic
depsipetides are part of a group enriched with any therapeutic properties, including antimicrobial,
antioxidant, and immunomodulatory and are also inhibitory of several biomolecules and biomolecular
processes, such as the activity of α-glucosidase, ch lesterol acyltransferase, xanthine oxidase,
and platelet aggregation [111]. Pr mising antiprotozoal activities were also observed f r compounds
belonging to this class, both again t malaria d toxopl smosis [110,112]. A library of compounds
isolated from the b auvericin-like family of the cyclic d psipeptides xhibited activity against
Plasmodium f lcipar within the IC50% range 0.24–3.4 µg/mL [110].
Metacytofilin (structure illustrated in Sche e 2) is a nat ral secondary metabolite produced by
Metarhizium fungus and belongs to the depsipetides’ group, ore specifically cyclic didepsipeptides,
which are characterized by possessing an ester group and an amide group in the same six-membered
ring [111,113,114]. This compound showed favorable results regarding its activity against T. gondii
parasites. Analogously to AMPs, metacytofilin acts through a dual mechanism, targeting both
the parasite directly through inhibition of its replicative cycle and the host immune system through
suppression of the inflammatory processes and stimulation of immune cells to combat the infection [112].
A detailed mechanism of action of this compound can be seen in Scheme 2.
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T. gondii-infected host cells.
It is also important to note that three main strains of T. gondii have been identified, type I, II, and
III, which differ in vi ulence and the epide iological pattern of occurrence [12]. The most common
strains affecting humans, nam ly immunosuppressed patients and those with congenital t xoplas osis,
are types I and II [12]. Metacytofilin was shown to inhibit the i tracellular growth of both type I
and type II strains [112]. Additional advantageous properties of metacytofilin include a favorable
pharmacokinetic profile, i.e., good gastrointestinal absorption, allowing for oral administration,
which in turn translates into low production and storage costs, as well as privileged properties for
distribution and administration.
3. Conclusions
Toxoplasmosis is a neglected infectious disease, mostly associated with disadvantaged populations.
The chemotherapeutic tools used to combat toxoplasmosis, in addition to not being exclusively used
for this infection, show reduced efficacy, due to the fast development of resistance by the parasite,
and, in most cases, toxicity to the host and high cost. In recent years, the scientific community has
intensified efforts in the search for new drugs for the treatment of toxoplasmosis that act in both the
chronic and acute phases of the disease, display safer profiles, and are able to reach organs, such as the
brain and the eyes. The knowledge gathered through intense research on Plasmodium spp. and malaria
allowed for the discovery of many therapeutic solutions that are useful not only in the treatment
of malaria but also as tools to fight other infectious diseases caused by protozoan parasites that
share parasite similarities and metabolic pathways, as is the case of toxoplasmosis. New studies
have spurred the id ntification of new pharmacological candidates, active on both Plasmo ium and
T. gondii parasites, highlighting classes like quinolones, endoperoxides, and pyrazolo[1,5-a]pyrimidines,
amo g others. Further research should therefor be undertak n with upmost urgency, in t e h p that,
in the futur , these results will promote an increase in the t erapeutic ar nal for toxoplas sis and
malaria, eliminating the gaps in the current che therapy.
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